The J. David Gladstone Institutes

The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone

Jae Kyu Ryu

Katerina Akassoglou

Anke Meyer-Franke

Warner C Greene

Mauricio Montano

Described herein is an animal model useful for identifying therapeutic agents that can inhibit the physiological effects or symptoms of COVID-19 infection, including the effects of the following on one or more organs of the animal: inflammation, oxidative stress, fibrin deposition, blood brain barrier breakdown, clotting, and vascular problems.

Animal model for SARS-CoV-2-spike induced coagulopathy

The present invention provides compositions exhibiting in vivo activity of fibrin in an in vitro setting, in vitro assays comprising such compositions, methods of producing such compositions, and methods of using such compositions and assays. The compositions of the invention include molecules with the biochemical properties of 1) high affinity binding to fibrin receptors and 2) activation of cell-signaling systems comparable to that observed in vivo by fibrin. The fibrin compositions of the invention are compatible both in biochemical assays and cell-based assays, and thus useful for in vitro assays for screening of test agents that modulate cell activation and/or signaling pathways mediated by fibrin or associated with fibrin activity.

Compositions and methods for in vitro assays of fibrin activity

The present invention provides non-human animal models of neuronal injury and/or cognitive dysfunction and methods of making and using such animal models. The animal models of the invention are particularly suited to assessing neurodegeneration in selected regions of interest in the CNS, and thus especially useful for testing the therapeutic efficacy of agents targeting neurodegeneration associated with aging, neurodegenerative diseases, autoimmunity and trauma (e.g., ischemia).

Growing community of inventors

San Francisco, CA, United States of America

Jae Kyu Ryu